Scarica l'app Stockscreener
1.73
0.57%
-0.01
Dopo l'orario di chiusura:
1.72
-0.01
-0.58%
Precedente Chiudi:
$1.74
Aprire:
$1.72
Volume 24 ore:
1.71M
Relative Volume:
1.45
Capitalizzazione di mercato:
$119.57M
Reddito:
-
Utile/perdita netta:
$-89.66M
Rapporto P/E:
-0.7147
EPS:
-2.4205
Flusso di cassa netto:
$-81.90M
1 W Prestazione:
-64.62%
1M Prestazione:
-73.51%
6M Prestazione:
-65.94%
1 anno Prestazione:
+18.49%
Intervallo 1D:
$1.65
$1.79
Intervallo di 1 settimana:
$1.32
$5.06
Portata 52W:
$0.8801
$7.80
Pepgen Inc Stock (PEPG) Company Profile
Nome
Pepgen Inc
Settore
Industria
Telefono
703-456-8000
Indirizzo
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Compare PEPG vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
1.73 | 119.57M | 0 | -89.66M | -81.90M | -2.4205 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-09 | Iniziato | Guggenheim | Buy |
| 2024-12-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-07-31 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-21 | Iniziato | H.C. Wainwright | Buy |
Pepgen Inc Borsa (PEPG) Ultime notizie
PepGen crashes after mid-stage trial data for muscle disorder therapy - MSN
PepGen stock plunges 26% on FDA partial clinical hold - Investing.com
PepGen Reports Encouraging Phase II FREEDOM2 DM1 Data at 5 mg/kg; 10 mg/kg Cohort Underway - National Today
Wedbush Maintains PepGen (PEPG) Outperform Recommendation - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - ChartMill
FDA places partial clinical hold on PepGen’s DM1 trial - Investing.com
PEPG Stock Price, Quote & Chart | PEPGEN INC (NASDAQ:PEPG) - ChartMill
Scholar Rock To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday - Sahm
Assay what? Eyes on Pepgen’s vim-sapping DM1 phase II - BioWorld MedTech
Assay what? Eyes on Pepgen’s DM1 phase II - BioWorld MedTech
Buy Rating on PepGen: DM1 Program De-Risked by Stronger Underlying Biology and Upside from Higher-Dose Cohorts - TipRanks
PEPG: FREEDOM2's 5 mg/kg cohort showed promising safety and efficacy, supporting dose escalation - TradingView
MACD Signal: What are the analyst revisions for NEOVIs PepGen Inc stock a good investment in YEAR2026 Volatility Report & Growth Focused Stock Reports - baoquankhu1.vn
PepGen Shares Fall After Data From Ongoing Phase 2 Study for Myotonic Dystrophy Type 1 Patients - MarketScreener
PepGen's 5 mg/kg Data Outlier: Is This a Prelude to a 10 mg/kg Comeback or Evidence of a Failed Strategy? - Bitget
PepGen Plunges On Mixed Phase 2 Data, But Higher Dose Could Offer Some Relief - Seeking Alpha
PepGen’s Stock Plummets Amid FDA Trial Hold and Market Reaction - StocksToTrade
PepGen (NASDAQ:PEPG) Price Target Lowered to $5.00 at Wedbush - MarketBeat
PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease - biospace.com
PepGen Inc. Shareholders Are Encouraged to Reach Out to - GlobeNewswire
A Quick Look at Today's Ratings for PepGen(PEPG.US), With a Forecast Between $3 to $20 - news.futunn.com
Why PEPG, SGMO, PHR are among top premarket losers today - MSN
PepGen: Modest FREEDOM2 Efficacy, Regulatory Overhang, and Competitive Pressures Underscore Sell Rating - TipRanks
Wedbush Cuts Price Target on PepGen to $5 From $9, Keeps Outperform Rating - MarketScreener
Why Is PepGen Stock Sinking Tuesday?PepGen (NASDAQ:PEPG) - Benzinga
PepGen posts trial data for muscle disorder drug (PEPG:NASDAQ) - Seeking Alpha
PepGen Inc. (PEPG) Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT DataSlideshow (NASDAQ:PEPG) 2026-03-31 - Seeking Alpha
PepGen reports ‘promising’ topline results from MAD cohort - TipRanks
PepGen stock tumbles 44% on disappointing trial results By Investing.com - Investing.com Canada
Movement Recap: Should I set a stop loss on PepGen Inc2026 Breakouts & Short-Term Trading Alerts - baoquankhu1.vn
PepGen Reports Early Phase 2 FREEDOM2-DM1 Topline Data - TipRanks
PepGen reports mixed results from DM1 trial, 10mg cohort ongoing By Investing.com - au.investing.com
PepGen reports favorable safety and splicing trends for 5 mg/kg cohort, on track for 10 mg/kg readout - TradingView
[8-K] PepGen Inc. Reports Material Event - Stock Titan
PepGen stock tumbles 44% on disappointing trial results - Investing.com
PepGen reports mixed results from DM1 trial, 10mg cohort ongoing - Investing.com
PepGen advances Phase 2 study with 10 mg/kg DM1 cohort under way - Traders Union
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data - Yahoo Finance
PepGen, Inc. (NASDAQ:PEPG) Short Interest Up 26.1% in March - MarketBeat
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD C - The National Law Review
S P Trends: Is PepGen Inc stock a smart retirement pick2026 Short Interest & Verified Stock Trade Ideas - baoquankhu1.vn
Swing Trade: Why is PepGen Inc stock going downLong Setup & Daily Profit Maximizing Tips - baoquankhu1.vn
US FDA puts partial clinical hold on PepGen's muscle disease drug trial - MSN
If You Invested $1,000 in PepGen Inc (PEPG) - Stock Titan
PepGen, Inc. (NASDAQ:PEPG) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
PEPG SEC FilingsPepGen Inc 10-K, 10-Q, 8-K Forms - Stock Titan
COMMODORE CAPITAL LP Acquires Additional Shares in PepGen Inc - GuruFocus
How much upside is left in PepGen (PEPG)? Wall Street analysts think 75.44% - MSN
Pepgen Inc Azioni (PEPG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):